PurposeWe aimed to describe the demographics, cancer MESHD
subtypes, comorbidities and outcomes of patients with a history of cancer MESHD
with COVID-19 MESHD
from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 MESHD
to patients diagnosed with COVID-19 MESHD
and patients hospitalized with influenza.
MethodsWe conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer MESHD
were included: i) diagnosed with COVID-19 MESHD
, ii) hospitalized with COVID-19 MESHD
, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death MESHD
. We reported demographics, cancer MESHD
subtypes, comorbidities, and 30-day outcomes.
ResultsWe included 118,155 patients with a cancer MESHD
history in the COVID-19 MESHD
diagnosed and 41,939 in the COVID-19 MESHD
hospitalized cohorts. The most frequent cancer MESHD
subtypes were prostate and breast cancer MESHD
(range: 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies MESHD
were also frequent, with non-Hodgkins lymphoma MESHD
being among the 5 most common cancer MESHD
subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized COVID-19 MESHD
cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer MESHD
subtypes, sex, age and comorbidities but lower occurrence of adverse events.
ConclusionPatients with a history of cancer MESHD
and COVID-19 MESHD
have advanced age, multiple comorbidities, and a high occurence of COVID-19 MESHD
-related events. Additionaly, hematological malignancies MESHD
were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.